NEW PRODUCT: COGNIVAID™
Moleac has just launched a new product, CognivAiD™, in Singapore!
A Focus on Neurology
Since Moleac was founded, our ambition is to provide new solutions to supplement the therapeutic armamentarium for conditions where significant unmet needs remain. To achieve this goal, we develop natural products according to international standards and commercialize our products worldwide.
Our products are developed by Moleac with scientific excellence and evidence-based approach.
Together with our R&D department and world renowned experts, we have successfully developed and marketed NeuroAiD, the world’s first post-stroke recovery treatment, helping patients to regain functional independence after a stroke or a traumatic brain injury by amplifying endogenous processes of brain repair. NeuroAiD is available in over 30 countries worldwide.
A growing international network
Patients taking NeuroAid yearly
Awards
Countries with Exclusive Partnership
Let’s talk about moleac with noemie & david picard
Moleac in a nutshell. Noemie, 9 years old, gets to know more about Moleac with David Picard, its co-founder and CEO.
Latest News
MOLEAC LAUNCHES COGNIVAID A NOVEL TARGETED PRODUCT FOR VASCULAR DEMENTIA
Moleac announced on 29th October 2022 the launch of CognivAiD™ the first-in-market specific product for Vascular Dementia (VaD) An optimized formulation of active extracts from Gingko, Ginseng and Saffron…
MOLEAC PTE LTD WINS SBR NATIONAL BUSINESS AWARD FOR PHARMACEUTICALS
Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.
Moleac is dedicated in finding, developing the company’s main goal…
Embracing World Stroke Day 2021
Stroke remains one of the main cause for disability worldwide. Moleac remains committed to helping patients Reconnect with their loved ones. We always place…
MOLEAC ANNOUNCES US FDA APPROVAL OF IND APPLICATION FOR PHASE 1 STUDY OF MLC1501 PROGRAMME IN POST-TRAUMATIC BRAIN INJURY RECOVERY
Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new…
